Alphavbeta6 PET in Radiation induced Lung fibrosis (EARL)
Research type
Research Study
Full title
Evaluation of changes to alphavbeta6 integrin in Radiation induced Lung fibrosis (EARL)
IRAS ID
216738
Contact name
Azeem Saleem
Contact email
Sponsor organisation
Imanova
Duration of Study in the UK
1 years, 8 months, 29 days
Research summary
This is a pilot study that aims to determine the feasibility of conducting Positron emission tomography (PET) imaging using [18F]-FBA-A20FMDV2 ([18F]-IMAFIB) in up to 12 patients with lung tumours undergoing radiotherapy. FBA-A20FMDV2 is a synthetic peptide that is known to bind to the alpha-v-beta-6 integrin. The alpha-v-beta-6 integrin plays a key role in trigering Transforming growth factor-β (TGFβ), which is the initial event in the initiation of fibrosis in a number of tissues.
In this study, we will perform PET imaging using the FBA-A20FMDV2 radiolabelled with fluorine-18, [18F]-FBA-A20FMDV2 ([18F]IMAFIB); radiotracer) and assess its uptake in regions of fibrosis using PET imaging. We will do this in patients due to have radiotherapy for their lung cancer or who have completed radiotherapy to their lung tumours. PET scans will be done in our newly installed PET-MR scanner for up to 65 minutes and then for up to 20 minutes in a PET-CT scanner. We will try to relate the radiotherapy doses in the different parts of the lung with the uptake of the radiotracer. We will also relate the PET scans acquired in the PET-MR scanner with that acquired in the PET-CT scanner to validate our PET-MR imaging methods.REC name
West Midlands - Black Country Research Ethics Committee
REC reference
17/WM/0084
Date of REC Opinion
17 Mar 2017
REC opinion
Further Information Favourable Opinion